

To, BSE Limited, 25, P. J. Towers, Dalal Street, Mumbai – 400 001 Ref: Company Scrip Code: 532834	To, Listing Department, National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 Ref: Symbol: CAMLINFINE Series: EQ
--	---

Dear Sir/Madam,

Sub: Outcome of the Board Meeting

The Board of Directors of the Company at its meeting held today i.e., 24th May, 2019, inter alia, has taken note and approved the following:

1. The Audited Financial Results (standalone and consolidated) for the quarter and year ended 31st March, 2019. The audited results along with audit reports are enclosed herewith as Annexure-1.
2. Appointment of Mr. Amol Shah (DIN: 00171006) as Independent Non-Executive Director at the ensuing 26th Annual General Meeting of the Company. Disclosure related to the same is enclosed herewith as Annexure -2.
3. Resignation tendered by Mr. Ajit Deshmukh (DIN: 00203706), Non-Executive Director from the directorship of the Company on personal grounds w.e.f. 24th May, 2019 from the conclusion of this meeting.
4. The Notice of the 26th Annual General Meeting scheduled to be held on Friday, 02nd August, 2019 inter alia to consider and adopt the audited financial statements (including the consolidated financial statements) of the Company for the financial year ended 31st March, 2019 and the reports of the Board of Directors and Auditors thereon.
5. Closure of the Register of Member and Share Transfer Books of the Company from 27th August, 2019 to 02nd August, 2019 (both days inclusive) for taking record of the Members of the Company for the purpose of 26th Annual General Meeting.

The meeting of Board of Directors commenced at 01.30 pm and concluded at 06.30 pm. Kindly take the above information on records.

Encl.: a/a.

Thanking You,

For Camlin Fine Sciences Limited


(Rahul Sawale)
Group Company Secretary



Registered Office:

Camlin Fine Sciences Ltd. F/11-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400093, India.
CIN: L74100MH1993PLC075361

+91 22 6700 1000

+91 22 2832 4404

corporate@camlinfs.com

www.camlinfs.com

Annexure-1



STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2019													
PART I	PARTICULARS	STANDALONE				CONSOLIDATED							
		QUARTER ENDED		YEAR ENDED		QUARTER ENDED		YEAR ENDED		QUARTER ENDED		YEAR ENDED	
		31.03.2019 (Audited)	31.12.2018 (Unaudited)	31.03.2018 (Audited)	31.03.2018 (Unaudited)	31.03.2019 (Audited)	31.12.2018 (Unaudited)	31.03.2018 (Audited)	31.03.2018 (Unaudited)	31.03.2019 (Audited)	31.12.2018 (Unaudited)	31.03.2019 (Audited)	31.03.2018 (Audited)
1	Revenue from operations	17,151.18	14,993.86	12,818.49	54,812.29	26,803.53	24,139.88	23,168.70	89,216.67	23,168.70	89,216.67	23,168.70	89,216.67
2	Other income	183.56	140.55	523.99	1,084.65	459.94	83.51	868.02	1,378.73	459.94	83.51	868.02	1,378.73
3	Total income	17,334.74	15,134.41	13,342.48	55,896.94	27,263.47	24,223.39	24,036.72	90,595.40	24,036.72	90,595.40	24,036.72	90,595.40
4	Expenses	12,276.49	11,715.62	8,805.05	39,570.84	15,308.38	11,661.86	11,078.08	46,928.06	11,078.08	46,928.06	11,078.08	46,928.06
	Purchase of stock in trade	257.97	98.55	884.67	547.65	237.95	287.42	2,539.50	2,617.41	237.95	287.42	2,539.50	2,617.41
	Charges in inventories of finished goods/WIP/stock in trade	495.22	(203.47)	(584.52)	746.42	(38.80)	756.58	(481.72)	(2,065.19)	(38.80)	756.58	(481.72)	(2,065.19)
	Excise duty	-	-	-	-	-	-	-	-	-	-	-	-
	Employee benefits expense	566.75	611.89	585.77	2,366.19	2,089.55	2,261.03	2,041.07	8,788.52	2,089.55	2,261.03	2,041.07	8,788.52
	Finance costs	521.84	165.01	618.32	2,034.37	736.97	1,105.74	415.66	3,670.73	736.97	1,105.74	415.66	3,670.73
	Depreciation and amortisation expense	224.73	226.48	221.13	908.83	906.15	731.29	680.16	2,899.32	906.15	731.29	680.16	2,899.32
	Other expenses	2,096.65	3,542.62	1,919.74	8,402.02	7,313.23	7,630.38	6,949.36	26,081.30	7,630.38	6,949.36	26,081.30	26,444.42
	Total Expenses	17,039.65	16,156.70	12,550.16	54,778.31	26,591.58	24,383.17	23,520.90	88,920.24	26,591.58	24,383.17	23,520.90	88,920.24
5	Profit/(Loss) before share of profit of associate (1-4)	295.09	(1,022.29)	792.32	1,418.63	671.89	(519.78)	515.82	1,675.16	671.89	(519.78)	515.82	1,675.16
6	Share of profit/(loss) of associate	-	-	-	-	(5.88)	(0.02)	18.84	(5.88)	-	-	18.84	(5.88)
7	Profit/(Loss) before tax (5-6)	295.09	(1,022.29)	792.32	1,418.63	666.01	(519.80)	534.66	1,669.28	666.01	(519.80)	534.66	1,669.28
8	Tax Expenses	83.47	(290.30)	-	320.41	268.71	(8.93)	167.36	1,382.98	268.71	(8.93)	167.36	1,382.98
9	- Current tax	(53.70)	(198.34)	670.25	25.40	(232.58)	(72.04)	793.18	(214.26)	(53.70)	(198.34)	670.25	(214.26)
10	- Deferred tax	29.77	(488.64)	670.25	345.81	36.13	(80.97)	960.54	1,368.70	36.13	(80.97)	960.54	1,368.70
11	Profit/(Loss) for the period (7-9)	265.32	(533.65)	122.07	1,072.82	629.88	(78.83)	(425.88)	300.58	629.88	(78.83)	(425.88)	300.58
12	Other comprehensive income	12.70	(48.63)	37.76	(46.30)	12.70	(48.63)	37.76	(46.30)	12.70	(48.63)	37.76	(46.30)
13	Items that will not be reclassified to profit or loss	(4.44)	16.67	(12.55)	16.18	(4.44)	16.67	(12.55)	16.18	(4.44)	16.67	(12.55)	16.18
14	Items that will be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	-	-
15	Exchange differences on translating the financial statements of foreign operations	-	-	-	-	-	-	-	-	-	-	-	-
16	Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	-	-
17	Other comprehensive income	8.26	(31.96)	25.21	(30.12)	8.26	(31.96)	25.21	(30.12)	8.26	(31.96)	25.21	(30.12)
18	Total comprehensive income for the period (9+10)	273.58	(565.61)	147.28	1,042.70	638.14	(110.79)	560.64	1,635.38	638.14	(110.79)	560.64	1,635.38
19	Profit/(loss) attributable to:												
20	Owners of the Company	265.32	(533.65)	122.07	1,072.82	629.88	(78.83)	(425.88)	300.58	629.88	(78.83)	(425.88)	300.58
21	Non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	-
22	Other comprehensive income attributable to:												
23	Owners of the Company	8.26	(31.96)	25.21	(30.12)	8.26	(31.96)	25.21	(30.12)	8.26	(31.96)	25.21	(30.12)
24	Non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	-
25	Total comprehensive income attributable to:												
26	Owners of the Company	273.58	(565.61)	147.28	1,042.70	638.14	(110.79)	560.64	1,635.38	638.14	(110.79)	560.64	1,635.38
27	Non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	-
28	Earnings per Share (EPS) of Rs.1/- per share	1,212.54	1,212.54	1,212.30	1,212.54	1,212.54	1,212.54	1,212.54	1,212.54	1,212.54	1,212.54	1,212.54	1,212.54
29	Basic (Rs.)	0.22	(0.44)	(0.26)	0.88	0.60	(0.17)	0.60	0.05	0.60	(0.17)	0.60	0.05
30	Diluted (Rs.)	0.22	(0.44)	(0.26)	0.88	0.60	(0.17)	0.60	0.05	0.60	(0.17)	0.60	0.05

Registered Office:
Camlin Fine Sciences Ltd./F/11-I-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400093, India.
CIN: L74100MH1993PLC075361

+91 22 6700 1000

+91 22 2832 4404

corporate@camlins.com

www.camlins.com



Notes to financial results:

- The above results which are published in accordance with Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements), 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 24, 2019. The financial results are in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time.
- The format for the audited/unaudited financial results as prescribed in SEBI's circular CIR/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with the requirements of SEBI's circular dated July 05, 2016, Ind AS and Schedule III (Division II) to the Companies Act, 2013, as amended, which are applicable to companies, that are required to comply with Ind AS.
- The figures for the quarters ended March 31 as reported in these results are the balancing figures between audited figures in respect of the years ended March 31 and the published year to date figures up to the end of the third quarter of the relevant financial years. Also, the figures upto the end of the third quarter had only been reviewed and not subjected to audit.
- On April 01, 2018, the Company has adopted Ind AS 115 - 'Revenue from Contracts with Customers'. The adoption of Ind AS 115 did not have any material impact on the results for quarter and year ended March 31, 2019.
- Sales for the quarter and year ended March 31, 2019 is net of Goods and Service Tax (GST), however the sales for the year ended March 31, 2018 are gross of excise duty. The net revenue from operations (net of GST / excise duty) as applicable are stated below:

Particulars	STANDALONE			CONSOLIDATED		
	QUARTER ENDED	YEAR ENDED	QUARTER ENDED	YEAR ENDED	YEAR ENDED	YEAR ENDED
	31.03.2019	31.03.2018	31.03.2019	31.03.2018	31.03.2019	31.03.2018
	(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Audited)
Net revenue from operations	16,791.93	14,706.82	33,432.69	39,906.96	26,471.46	22,914.02
						87,843.44
						71,229.65

6 Other income / Other expense above includes net foreign exchange gain / (loss) for each reporting period as under:

Particulars	STANDALONE			CONSOLIDATED		
	QUARTER ENDED	YEAR ENDED	QUARTER ENDED	YEAR ENDED	YEAR ENDED	YEAR ENDED
	31.03.2019	31.03.2018	31.03.2019	31.03.2018	31.03.2019	31.03.2018
	(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Audited)
Other Income	-	-	281.14	279.13	-	-
Other Expense	(374.86)	(1,086.64)	180.78	(462.54)	(532.78)	(73.49)
Total Exchange gain / (loss)	(374.86)	(1,086.64)	180.78	281.14	170.31	(73.49)
						37.08

7 Standalone finance costs for current year and current quarter includes exchange gain on revaluation of foreign currency borrowings amounting to Rs. 398.68 lakhs and Rs. 112.65 lakhs respectively. Consolidated finance costs for current year and current quarter includes exchange (loss) on revaluation of foreign currency borrowings amounting to Rs. (124.12) lakhs and Rs. (207.51) lakhs respectively.

8 Deferred tax expense for the current year include MAT Credit entitlement of Rs. 320.41 lakhs.

9 Out of the net proceeds of Rs. 14,587.17 lakh, pursuant to QIP issue on November 23, 2017, the Company has utilized the proceeds as per the objects of the issue as follows:

Particulars	(Rs. In Lakhs)
Capital expenditure including capital advances	2,117.88
Investments in / loans to subsidiaries	2,657.25
General corporate purposes	9,812.05
Total	14,587.18

- The Company has invested Rs. 56.01 lakh in the share capital of Solentia North America Inc., its wholly owned subsidiary Company (the subsidiary) and given a loan of Rs. 255.64 lakh to it upto March 31, 2019. The subsidiary has negative net worth as at March 31, 2019 and is dependent upon the Company to enable it to meet its obligations as they become due. Based on the proposed plans for the subsidiary, management believes the loan to be fully recoverable and further believes that there is no diminution other than temporary in its investment in the share capital of the subsidiary.
- During the year ended March 31, 2019, the Company has issued and allotted 24,625 equity shares of Rs.1 each respectively at a premium of Rs. 66 per equity share aggregating to Rs. 16.50 lakh under Employees Stock Option Scheme. 15800 stock options have lapsed during the year.
- Consolidated Gross sales / Income from operation is net of Sales/Purchase between company and its subsidiary companies.
- On July 12, 2017, the Company had acquired 51% equity stake in CFS Wanglong Flavours (Ningbo) Co. Ltd. On April 11, 2018, a step down subsidiary of the Company, CFS Argentina SA was incorporated. On July 27, 2018, CFS Chile SpA, a step down subsidiary of the company was incorporated. On April 09, 2018, CFS Pahang Asia Pte. Ltd., a subsidiary of the Company was incorporated. Results of these subsidiaries have been consolidated for the current period. Hence the corresponding figures for quarter and year ended March 31, 2018 are not comparable.
- The Company's operations constitute a single business segment in Fine Chemicals.
- Figures for previous periods have been regrouped/rearranged wherever necessary.



Place: Mumbai
Date: May 24, 2019

Registered Office:

Camlin Fine Sciences Ltd. F/11-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400093, India.
CIN: L74100MH1993PLC075361

+91 22 6200 1000

+91 22 2832 4404

corporate@camlinfs.com

www.camlinfs.com



BALANCE SHEET



PARTICULARS		STANDALONE		CONSOLIDATED	
		31.03.2019	31.03.2018	31.03.2019	31.03.2018
		(Audited)	(Audited)	(Audited)	(Audited)
(1)	ASSETS				
	Non-Current Assets				
(a)	Property, Plant and Equipment	7,892.90	6,834.83	20,854.45	20,661.85
(b)	Capital work-in-progress	5,237.16	1,202.84	5,364.48	1,285.28
(c)	Investment Property	207.19	207.19	207.19	207.19
(d)	Goodwill	-	-	4,443.31	4,462.86
(e)	Other Intangible Assets	66.80	115.83	1,739.29	2,477.88
(f)	Intangible Assets under development	1,610.46	781.10	535.84	76.44
(g)	Investment in associate	-	-	13.36	19.24
(h)	Financial Assets				
(i)	Investments	6,571.95	4,000.71	714.25	714.25
(ii)	Loans	2,878.17	1,884.96	1,113.84	65.66
(j)	Deferred tax assets (net)	120.70	168.02	4,124.60	3,958.16
(k)	Income tax assets	358.36	282.86	739.69	680.74
	Other non-current assets	2,400.44	485.40	1,581.35	485.40
	Total Non-current Assets	27,344.13	15,963.74	41,431.65	35,094.95
(2)	Current Assets				
(a)	Inventories	10,930.99	11,481.27	28,541.39	23,901.90
(b)	Financial assets				
(i)	Investments	325.49	10,807.63	325.49	10,807.63
(ii)	Trade receivables	26,185.91	21,142.14	20,931.98	20,534.78
(iii)	Cash and cash equivalents	1,889.04	179.32	5,321.36	3,847.62
(iv)	Other bank balances	5,023.02	959.83	5,023.02	960.86
(v)	Loans	1,613.34	2,340.80	307.14	343.83
(vi)	Other financial assets	2,211.80	1,924.45	1,074.75	622.96
(c)	Other current assets	2,572.75	2,978.88	5,722.51	5,535.29
	Total Current Assets	50,752.34	51,814.32	67,247.64	66,554.87
	TOTAL ASSETS	78,096.47	67,778.06	1,08,679.29	1,01,649.82
(1)	EQUITY AND LIABILITIES				
	EQUITY				
(a)	Equity Share Capital	1,212.54	1,212.30	1,212.54	1,212.30
(b)	Other Equity	33,530.11	31,933.54	35,875.57	35,903.97
(c)	Non-Controlling Interest	-	-	5,939.91	6,221.73
	Total Equity	34,742.65	33,145.84	43,028.02	43,338.00
(2)	LIABILITIES				
	Non-current Liabilities				
(a)	Financial Liabilities				
(i)	Borrowings	11,110.46	1,449.86	18,488.51	11,024.49
(b)	Provisions	236.88	196.40	236.88	196.40
(c)	Deferred tax liabilities (net)	-	-	11.84	-
(d)	Other non-current liabilities	315.60	171.06	177.39	-
	Total Non-Current Liabilities	11,662.94	1,817.32	18,914.62	11,220.89
(3)	Current Liabilities				
(a)	Financial Liabilities				
(i)	Borrowings	19,900.13	20,029.44	24,697.47	24,678.60
(ii)	Trade Payables				
(A)	Total outstanding dues of micro enterprises and small enterprises; and	400.09	45.88	400.09	45.88
(B)	Total outstanding dues of creditors other than micro enterprises and small enterprises	10,188.82	11,373.30	16,675.59	17,733.13
(iii)	Other financial liabilities	977.23	967.22	3,481.99	3,057.34
(b)	Other current liabilities	146.09	334.83	729.04	847.13
(c)	Provisions	29.74	35.86	703.69	700.48
(d)	Current tax liabilities (net)	48.78	28.37	48.78	28.37
	Total Current Liabilities	31,690.88	32,814.90	46,736.65	47,090.93
	TOTAL EQUITY AND LIABILITIES	78,096.47	67,778.06	1,08,679.29	1,01,649.82



FOR CAMLIN FINE SCIENCES LIMITED

Ashish S. Dandekar
Managing DirectorPlace: Mumbai
Date: May 24, 2019

Registered Office:

Camlin Fine Sciences Ltd. F/11-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400093, India.
CIN: L74100MH1993PLC075361

+91 22 6700 1000

+91 22 2832 4404

corporate@camlinfs.com

www.camlinfs.com

KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

Auditor's Report on Quarterly and Annual Standalone Financial Results Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The Board of Directors
Camlin Fine Sciences Limited
F/11-12, WICEL,
Opposite SEEPZ Central Road,
Andheri (East),
Mumbai - 400093.

1. We have audited the accompanying Standalone Financial Results of Camlin Fine Sciences Limited ("the Company") for the quarter and year ended March 31, 2019 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. These quarterly and annual standalone financial results have been prepared on the basis of the standalone financial statements, which are the responsibility of the Company's Management. Our responsibility is to express an opinion on these standalone financial results based on our audit of such standalone financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, and other accounting principles generally accepted in India. Attention is drawn to the fact that the figures for the quarters ended March 31, as reported in these results are the balancing figures between audited figures in respect of the years ended March 31, and the published year to date figures up to the end of the third quarter of the relevant financial year. Also the figures up to the end of the third quarter had only been reviewed and not subjected to audit.
2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those Standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe our audit provides a reasonable basis for our opinion.
3. We draw attention to Note 10 to the Notes to financial results relating to an investment made by the Company in the share capital of Solentus North America Inc., its wholly owned subsidiary company amounting to Rs. 56.01 Lakhs and to whom it has also advanced a loan aggregating to Rs. 255.64 Lakhs. The subsidiary has negative net worth as at March 31, 2019 and is dependent upon the Company to enable it to meet its obligations as they become due. In the opinion of the management, the fall in value of the equity shares is temporary and the recoverability of the above loan is dependent on successful implementation of management's future plans in respect of the said subsidiary.

Our opinion is not modified in respect of the above matter.



LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001
TEL.: (91) (22) 6158 6200, 6158 7200 FAX : (91) (22) 6158 6275

**KALYANIWALLA
& MISTRY LLP**

4. In our opinion and to the best of our information and according to the explanations given to us, these quarterly as well as year to date financial results:
- i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, in this regard; and
 - ii. give a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the profit, total comprehensive income and other financial information for the quarter and year ended March 31, 2019.

For KALYANIWALLA & MISTRY LLP
CHARTERED ACCOUNTANTS
Firm Registration Number 104607W/W100166



FARHAD M. BHESANIA
PARTNER
Membership Number 127355
Place: Mumbai
Date: May 24, 2019

KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

Auditor's Report on Quarterly and Annual Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

The Board of Directors
Camlin Fine Sciences Limited
F/11-12, WICEL,
Opposite SEEPZ Central Road,
Andheri (East), Mumbai – 4000093.

1. We have audited the accompanying Statement of Consolidated Financial Results of Camlin Fine Sciences Limited ("the Company"), and its subsidiaries (the Company and its subsidiaries together referred to as the "Group") and an associate for the quarter and year ended March 31, 2019 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. These quarterly and annual consolidated financial results have been prepared on the basis of consolidated financial statements, which are the responsibility of the Company's Management. Our responsibility is to express an opinion on these consolidated financial results based on our audit of such consolidated financial statements, which have been prepared in accordance with the Indian Accounting Standards (Ind AS), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, and other accounting principles generally accepted in India. Attention is drawn to the fact that the figures for the quarters ended March 31, as reported in these results are the balancing figures between audited figures in respect of the year ended on March 31, and the published year to date figures up to the end of the third quarter of the relevant financial years. Also the figures up to the end of the third quarter had only been reviewed and were not subjected to audit.
2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.
3. We did not audit the financial results of eleven subsidiaries incorporated outside India and a subsidiary in India included in the consolidated quarterly and annual consolidated financial results, whose consolidated financial statements reflect total asset of Rs. 67,494.75 lakhs as at March 31, 2019; as well as the total revenue of Rs. 20,076.97 lakhs and Rs. 75,671.22 lakhs for the quarter and year ended on that date respectively and for an associate whose share of net loss of Rs. 5.88 lakhs, as considered in the consolidated financial results. These financial statements and other financial information have been audited by other auditors whose report has been furnished to us by the Management and our opinion on the quarterly and annual consolidated financial results, to the extent they have been derived from such financial statements is based solely on the report of such other auditors. Our report on the statement is not modified in respect of this matter.



LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001
TEL.: (91) (22) 6158 6200, 6158 7200 FAX: (91) (22) 6158 6275

4. These subsidiaries are located outside India whose financial results and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been audited by other auditors under generally accepted auditing standards applicable in their respective countries. The Company's management has converted the financial results of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India (Indian Accounting Standards 'Ind AS'). We have audited these conversion adjustments made by the Company's management. Our conclusion in so far as it relates to the balances and affairs of such subsidiaries located outside India is based on the report of the other auditors and the conversion adjustments made by the management of the Company and audited by us.

Our report on the statement is not modified in respect of these matters.

5. We did not audit the financial results of five subsidiaries incorporated outside India included in the consolidated quarterly and annual consolidated financial results, whose consolidated financial statement reflect total asset of Rs. 1,339.36 lakhs as at March 31, 2019; as well as the total revenue of Rs. 294.31 lakhs and Rs. 374.15 lakhs for the quarter and year ended on that date respectively. These financial results of five subsidiaries are not audited as of the date of this report and have been included in the Unaudited Consolidated Financial Results on the basis of the Unaudited Management Accounts.

Our report on the Statement is not modified in respect of our reliance on the Unaudited Management Accounts and other financial information furnished by the Management.

6. Based on our audit and on consideration of report of other auditors as referred to in paragraph 4 above, in our opinion and to the best of our information and according to the explanations given to us, these quarterly and annual consolidated financial results:

- i. include the quarterly and annual financial results of the following entities:

- a. CFCL Mauritius Pvt. Ltd.
- b. CFS do Brasil Indústria, Comércio, Importação e Exportação de Aditivos Alimentícios Ltda.
- c. Solentus North America Inc
- d. CFS Europe S.P.A
- e. CFS North America LLC
- f. Dresen Quimica SAPI De C.V.
- g. Industrias Petrotec De Mexico S.A. de C.V.
- h. Nuvel, S.A.C.
- i. Britec, S.A
- j. Inovel, S.A.S.
- k. Grinel, S.A
- l. CFS International Trading (Shanghai) Ltd
- m. Chemolutions Chemicals Ltd.
- n. CFS Wanglong Flavours (Ningbo) Co. Ltd.
- o. CFS Pahang Asia Pte. Ltd.
- p. CFS Argentina S.A.
- q. CFS Chile S.p.A
- r. Fine Lifestyle Brands Ltd.

- ii. have been presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 in this regard; and



**KALYANIWALLA
& MISTRY LLP**

- iii. give a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated profit, consolidated total comprehensive income and other financial information of the Group for the quarter as well as for the year ended March 31, 2019.

For KALYANIWALLA & MISTRY LLP
CHARTERED ACCOUNTANTS
Firm Registration Number 104607W/W100166



FARHAD M. BHESANIA
PARTNER
Membership Number 127355
Place: Mumbai
Dated: May 24, 2019

Registered Office:

Camlin Fine Sciences Ltd. 7/11-12, VICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400093, India.
CIN: L74100MH1993PLC075361

+91 22 6700 1000

+91 22 2832 4404

corporate@camlins.com

www.camlins.com

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2019												
No.	PARTICULARS	STANDALONE				CONSOLIDATED						(Rs. in Lakhs)
		QUARTER ENDED		YEAR ENDED		QUARTER ENDED		YEAR ENDED		YEAR ENDED		
		31.03.2019	31.12.2018	31.03.2018	31.03.2019	31.03.2019	31.12.2018	31.03.2018	31.03.2019	31.03.2018	31.03.2018	
1	Total Income from Operations	17,151.18	14,993.86	12,818.49	54,812.29	26,803.53	24,139.88	23,168.70	89,216.67	89,216.67	72,276.17	
2	Net Profit/(Loss) from ordinary activities after tax	265.32	(533.65)	122.07	1,072.82	629.88	(78.83)	(425.88)	300.58	300.58	(2,397.22)	
3	Net Profit/(Loss) for the period after tax and non-controlling interests (after extraordinary items)	265.32	(533.65)	122.07	1,072.82	727.22	(203.56)	(309.92)	57.72	57.72	(2,964.31)	
4	Total Comprehensive Income for the period	273.58	(565.61)	147.28	1,042.70	944.09	(521.71)	169.62	353.91	353.91	(1,160.71)	
5	Equity Share Capital	1,212.54	1,212.54	1,212.30	1,212.54	1,212.54	1,212.54	1,212.30	1,212.54	1,212.54	1,212.30	
6	Reserves (excluding revaluation reserves as shown in the Balance Sheet of previous year)	-	-	-	-	-	-	-	-	-	-	
7	Earnings per share (before and after extraordinary items) (of Re 1/-each)	0.22	(0.44)	(0.26)	0.88	0.60	(0.17)	(0.66)	0.05	0.05	(3.07)	
	-Basic Rs.	0.22	(0.44)	(0.26)	0.88	0.60	(0.17)	(0.66)	0.05	0.05	(3.07)	
	-Diluted Rs.	0.22	(0.44)	(0.26)	0.88	0.60	(0.17)	(0.64)	0.05	0.05	(3.01)	

The above information is an extract of the detailed format of audited results for the quarter and year ended March 31, 2019 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the audited results for the quarter and year ended March 31, 2019 are available on the Company's website, www.camlins.com and the Stock Exchange websites i.e. www.bseindia.com and www.nseindia.com

FOR CAMLIN FINE SCIENCES LIMITED

Ashish S. Dandekar

Ashish S. Dandekar
Managing Director



CFS Camlin
Fine Sciences

Place: Mumbai
Date: May 24, 2019

Annexure -2

The Board on the recommendation of the Nomination and Remuneration Committee are recommending the appointment of Mr. Amol Shah (DIN: 00171006), as an Independent Director to the shareholders at the ensuing 26th Annual General Meeting of the Company for the term of 5 (five) years from the date of the 26th Annual General Meeting.

Mr. Amol Shah graduated as Bachelor of science in engineering from University of Kent, Canterbury. He pursued his MBA from University of Southern California. He is also an alumnus of the prestigious Harvard Business School where he pursued an OPM (Owners, Proprietors & Managers) course. He has played a pivotal role in the management and growth of the MJ Group. With his focus on effective management strategies & his marketing prowess, he has driven MJ group towards achieving new heights across businesses. MJ is a multi faceted, multi dimensional business Group with manufacturing activities covering Human Healthcare, Flavors/Fragrances compounds, Plant protection and water treatment chemicals and has manufacturing locations in Maharashtra and Gujarat in India, and Dubai in the UAE, and with offices in London, Uzbekistan and Moscow.

Mr. Shah is Managing Director of the MJ Group and he possesses more than 25 years of experience in the industry. Mr. Shah does not hold any shares in the Company and is not related to any of the Directors.



 Registered Office:

Camlin Fine Sciences Ltd. F/11-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400093, India.
CIN: L74100MH1993PLC075361



+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com